MNMD Latest Quarter's Earnings
| Announce Date | 11/07/2024 |
| EPS Normalized Actual | $-0.27 (Beat by $0.02) |
| EPS GAAP Actual | $-0.27 (Beat by $0.02) |
| Revenue Actual | $0B |
| Revenue Surprise | Beat by $0M |
Upcoming Quarter's Earnings
| Announce Date | 03/30/2025 (Pre-Market) |
| EPS Normalized Estimate | $-0.355 |
| EPS GAAP Estimate | $-0.355 |
| Revenue Estimate | $0B |
Annual EPS Estimate
| Fiscal Period Ending | EPS Estimate | Forward PE | Low | High | # of Analysts |
|---|---|---|---|---|---|
| Dec 2028 | 1.238 | 6.04 | 1.238 | 1.238 | 2 |
| Dec 2027 | -0.596 | -12.54 | -0.596 | -0.596 | 1 |
Quarterly EPS History
| Period | EPS | Beat / Miss | Revenue | YoY | Beat / Miss |
|---|---|---|---|---|---|
| FQ4 2016 (Nov 2016) | -2.05 | -2.05 | 0B | NAN% | 0M |
| FQ1 2017 (Feb 2017) | -1.35 | -1.35 | 0B | NAN% | 0M |
| FQ2 2017 (May 2017) | -1.75 | -1.75 | 0B | NAN% | 0M |
| FQ3 2017 (Aug 2017) | -1.67 | -1.67 | 0B | NAN% | 0M |
| FQ4 2017 (Nov 2017) | -0.53 | -0.53 | 0B | NAN% | 0M |
| FQ1 2018 (Feb 2018) | -0.78 | -0.78 | 0B | NAN% | 0M |
| FQ2 2018 (May 2018) | -1.51 | -1.51 | 0B | NAN% | 0M |
| FQ3 2018 (Aug 2018) | -0.62 | -0.62 | 0B | NAN% | 0M |
Quarterly Estimates Summary
FQ4 Announce Date
03/30/2025 (Pre-Market)
Consensus EPS Estimates
-0.355
Consensus Revenue Estimates
0B
Consensus EPS Estimates
| Fiscal Period Ending | EPS Estimate | YoY Growth(%) | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ4 2025 (Oct 2025) | -0.36 | -- | -0.36 | -0.36 | 2 |
| FQ3 2025 (Jul 2025) | -0.36 | 99.94 | -0.36 | -0.36 | 2 |
| FQ2 2025 (Jun 2025) | -0.3575 | -- | -0.3575 | -0.3575 | 5 |
| FQ1 2025 (Mar 2025) | -0.355 | -- | -0.355 | -0.355 | 5 |
Consensus Revenue Estimates
| Fiscal Period Ending | Revenue Estimate | YoY Growth(%) | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ4 2025 (Oct 2025) | 0B | -- | 0B | 0B | 2 |
| FQ3 2025 (Jul 2025) | 0B | -- | 0B | 0B | 2 |
| FQ2 2025 (Jun 2025) | 0B | -- | 0B | 0B | 0 |
| FQ1 2025 (Mar 2025) | 0B | -- | 0B | 0B | 0 |
Quarterly Estimates Revisions
EPS # of Up Revisions
4
EPS # of Down Revisions
4
Revenue # of Up Revisions
6
Revenue # of Down Revisions
3
Consensus EPS Revision Trend
| Fiscal Period Ending | EPS Estimate | YoY Growth | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ4 2021 (Dec 2021) | 0.41 | -12.52% | 0.39 | 0.48 | 20 |
| FQ1 2022 (Mar 2022) | 0.59 | 6.89% | 0.55 | 0.62 | 15 |
| FQ2 2022 (Jun 2022) | 0.70 | 2.62% | 0.61 | 0.74 | 15 |
| FQ3 2022 (Sep 2022) | 0.68 | 4.62% | 0.65 | 0.70 | 15 |
Consensus Revenue Revision Trend
| Fiscal Period Ending | EPS Estimate | YoY Growth | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ4 2021 (Dec 2021) | 0.41 | -12.52% | 0.39 | 0.48 | 20 |
| FQ1 2022 (Mar 2022) | 0.59 | 6.89% | 0.55 | 0.62 | 15 |
| FQ2 2022 (Jun 2022) | 0.70 | 2.62% | 0.61 | 0.74 | 15 |
| FQ3 2022 (Sep 2022) | 0.68 | 4.62% | 0.65 | 0.70 | 15 |
Earnings Surprise Summary
EPS # of Beats
0
EPS # of Misses
8
EPS # of in-lines
0
Revenue # of Beats
0
Revenue # of Misses
0
Revenue # of in-lines
8
Earnings Surprise (EPS) - Actual vs Consensus
| Earnings Date | EPS Estimate | EPS Actual | Surprise | Surprise % |
|---|---|---|---|---|
| FQ4 2016 (Nov 2016) | -2.05 | -2.05 | 100% | |
| FQ1 2017 (Feb 2017) | -1.35 | -1.35 | 100% | |
| FQ2 2017 (May 2017) | -1.75 | -1.75 | 100% | |
| FQ3 2017 (Aug 2017) | -1.67 | -1.67 | 100% | |
| FQ4 2017 (Nov 2017) | -0.53 | -0.53 | 100% | |
| FQ1 2018 (Feb 2018) | -0.78 | -0.78 | 100% | |
| FQ2 2018 (May 2018) | -1.51 | -1.51 | 100% | |
| FQ3 2018 (Aug 2018) | -0.62 | -0.62 | 100% |
Revenue Surprise - Actual vs Consensus
| Earnings Date | Revenue Estimate | Revenue Actual | Surprise | Surprise % |
|---|---|---|---|---|
| FQ4 2016 (Nov 2016) | $0B | $0B | $0M | NAN% |
| FQ1 2017 (Feb 2017) | $0B | $0B | $0M | NAN% |
| FQ2 2017 (May 2017) | $0B | $0B | $0M | NAN% |
| FQ3 2017 (Aug 2017) | $0B | $0B | $0M | NAN% |
| FQ4 2017 (Nov 2017) | $0B | $0B | $0M | NAN% |
| FQ1 2018 (Feb 2018) | $0B | $0B | $0M | NAN% |
| FQ2 2018 (May 2018) | $0B | $0B | $0M | NAN% |
| FQ3 2018 (Aug 2018) | $0B | $0B | $0M | NAN% |
MNMD Ratings Summary
MNMD Quant Ranking
